A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects

Trial Profile

A Phase 2, Randomized, Open-label, Ascending, Sequential Dose Group, Multiple Dose Study of the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of CMX157 in HBV-infected Subjects

Completed
Phase of Trial: Phase I/II

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Tenofovir exalidex (Primary) ; Tenofovir disoproxil fumarate
  • Indications Hepatitis B
  • Focus Adverse reactions; Proof of concept; Therapeutic Use
  • Sponsors ContraVir Pharmaceuticals
  • Most Recent Events

    • 24 Oct 2017 Results of phase IIa portion of this study presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
    • 12 Sep 2017 Status changed from recruiting to completed.
    • 08 Aug 2017 According to a ContraVir Pharmaceuticals media release, data from the study will be presented at the American Association for the Study of Liver Diseases (AASLD).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top